Pharmaceutical Biotechnology Interview Questions

Biopharmaceuticals (biologics) are therapeutic products derived from living organisms or their components, including proteins, antibodies, vaccines, and nucleic acids. They differ from traditional small molecule drugs in several ways: larger molecular size (thousands to millions of Daltons vs hundreds), complex 3D structure essential for function, produced through biological processes (fermentation, cell culture) rather than chemical synthesis, sensitive to temperature and handling conditions, administered by injection rather than orally, highly specific with fewer off-target effects, and more expensive to develop and manufacture. Examples include insulin, monoclonal antibodies, and vaccines.

Vaccines can be classified by their composition: 1) Live attenuated - weakened pathogens that replicate but don't cause disease (MMR, oral polio). 2) Inactivated/killed - whole pathogens killed by heat or chemicals (flu shot, hepatitis A). 3) Subunit/protein - purified antigens or recombinant proteins (hepatitis B, HPV). 4) Toxoid - inactivated toxins (tetanus, diphtheria). 5) Conjugate - polysaccharide antigens linked to carrier proteins for better immune response (pneumococcal, Hib). 6) mRNA - genetic instructions to produce antigen (COVID-19 Pfizer, Moderna). 7) Viral vector - modified virus delivers antigen genes (COVID-19 AstraZeneca, J&J). Each type has advantages in terms of safety, efficacy, production complexity, and cold chain requirements.

A monoclonal antibody (mAb) is an antibody produced by a single clone of B cells, recognizing a single epitope with high specificity. Traditional production uses hybridoma technology: immunize mice with antigen, fuse spleen B cells with myeloma cells to create immortal antibody-producing hybridomas, screen for desired specificity, and grow selected clones. Modern production uses recombinant DNA technology in mammalian cell lines (CHO, HEK293) for better scalability. Antibodies can be murine (-omab), chimeric (-ximab), humanized (-zumab), or fully human (-umab). Applications include cancer therapy (rituximab), autoimmune diseases (adalimumab), and infectious diseases. The global mAb market exceeds $150 billion.

Drug development progresses through defined stages: 1) Discovery - target identification, lead compound discovery, in vitro testing. 2) Preclinical - animal studies for safety, toxicology, pharmacokinetics (ADME). IND application to FDA. 3) Phase I trials - first-in-human, 20-100 healthy volunteers, safety and dosing (6-12 months). 4) Phase II trials - 100-500 patients with disease, efficacy and side effects (1-2 years). 5) Phase III trials - 1000-5000 patients, large-scale efficacy, comparison to existing treatments (2-4 years). NDA/BLA submission. 6) FDA review and approval (6-12 months). 7) Phase IV - post-market surveillance for long-term effects. Total development typically takes 10-15 years with ~$1-2 billion cost and <10% success rate from preclinical to approval.

Recombinant human insulin is produced using genetically engineered microorganisms. The process involves: 1) Cloning human insulin genes (A and B chains) into expression vectors. 2) Transforming E. coli or yeast (Saccharomyces cerevisiae) with expression constructs. 3) Growing cultures in fermenters under controlled conditions. 4) Expressing insulin as inclusion bodies (E. coli) or secreted protein (yeast). 5) Cell harvest and lysis if needed. 6) Purification through chromatography (ion exchange, reverse phase, size exclusion). 7) Refolding and joining A and B chains with correct disulfide bonds. 8) Formulation with zinc and preservatives. Insulin analogs (lispro, glargine) are created by modifying the amino acid sequence for different pharmacokinetic profiles.

An adjuvant is a substance added to vaccines to enhance the immune response to the antigen. Adjuvants work by: activating innate immune cells (dendritic cells, macrophages), creating a depot effect for slow antigen release, promoting antigen uptake and presentation, and stimulating danger signals that enhance adaptive immunity. Common adjuvants include: aluminum salts (alum) - most widely used, induces Th2 response; MF59 - squalene oil-in-water emulsion; AS01/AS04 - used in shingles and HPV vaccines; CpG oligonucleotides - TLR9 agonists. Adjuvants allow dose sparing (less antigen needed), improve responses in immunocompromised individuals, and enable single-dose regimens. Selection depends on the desired immune response type.

IgG antibodies have a Y-shaped structure consisting of four polypeptide chains: two identical heavy chains (~50 kDa each) and two identical light chains (~25 kDa each), connected by disulfide bonds. Key regions include: Fab (Fragment antigen-binding) - contains variable regions (VH and VL) that form the antigen-binding site with CDRs (Complementarity Determining Regions) providing specificity. Fc (Fragment crystallizable) - constant region that interacts with immune cells and complement, determining effector functions. The hinge region provides flexibility between Fab and Fc. Glycosylation at Asn297 in CH2 domain is critical for Fc receptor binding and effector functions. Understanding structure guides antibody engineering for improved properties.

Good Manufacturing Practice (GMP) is a system of regulations ensuring pharmaceutical products are consistently produced and controlled according to quality standards. Key GMP principles include: documented procedures for all processes; qualified and trained personnel; suitable facilities and equipment; appropriate environmental controls and cleanliness; validated processes and methods; quality control testing of raw materials and finished products; traceability through batch records; handling of deviations and complaints; and regular audits. cGMP (current GMP) reflects that standards evolve. GMP is required by regulatory agencies (FDA, EMA) and covers all aspects from raw materials to distribution. Non-compliance can result in warning letters, product recalls, or facility shutdown.

A biosimilar is a biologic product highly similar to an already-approved reference biologic, with no clinically meaningful differences in safety, purity, or potency. Unlike generics (exact copies of small molecule drugs), biosimilars cannot be identical due to the complexity of biologics and manufacturing variability. Biosimilar approval requires: analytical similarity studies (structure, function), animal studies (toxicity), and clinical studies (pharmacokinetics, immunogenicity, efficacy). The regulatory pathway is abbreviated compared to new biologics but more rigorous than generics. Biosimilars offer cost savings (15-30% less than reference products) and increased patient access. Examples include biosimilar adalimumab (Humira), trastuzumab (Herceptin), and insulin glargine.

Different expression systems are chosen based on protein requirements: 1) E. coli - fast, inexpensive, high yields; lacks glycosylation; used for insulin, growth hormone. 2) Yeast (S. cerevisiae, Pichia pastoris) - eukaryotic folding, simple glycosylation; hepatitis B vaccine, insulin. 3) Mammalian cells (CHO, HEK293) - complex human-like glycosylation essential for antibodies; most therapeutic proteins; expensive, slower. 4) Insect cells (baculovirus system) - post-translational modifications, good for complex proteins; vaccines. 5) Plant cells - scalable, no animal pathogens; some vaccines and enzymes. 6) Transgenic animals - for rare proteins; antithrombin from goat milk. Selection factors include glycosylation needs, protein complexity, cost, scalability, and regulatory considerations.

Active immunization stimulates the body's immune system to produce its own antibodies and memory cells through exposure to antigens (via vaccines or natural infection). It takes weeks to develop but provides long-lasting protection through immunological memory. Passive immunization provides pre-formed antibodies from external sources, offering immediate but temporary protection (weeks to months). Sources include: maternal antibodies (transplacental, breast milk), immune globulin preparations (IVIG, specific immunoglobulins for rabies, hepatitis B), and monoclonal antibody therapies. Passive immunization is used for post-exposure prophylaxis, immunocompromised patients, and when immediate protection is needed. Both can be combined (rabies treatment).

Target identification is the process of finding disease-relevant biological molecules (usually proteins) that can be modulated by drugs. Approaches include: genomics and transcriptomics (identifying disease-associated genes), proteomics (protein expression differences), genetic studies (GWAS, Mendelian diseases), pathway analysis, and literature mining. Target validation confirms the target's role in disease and druggability through: genetic knockdown/knockout (siRNA, CRISPR), chemical probes, animal disease models, biomarker studies, and analysis of human genetic data (loss-of-function variants). A good target should be: causally linked to disease, druggable (accessible binding site), selective (avoid off-target effects), and have a measurable biomarker. Poor target selection is a major cause of drug development failure.

An Antibody-Drug Conjugate (ADC) combines the targeting specificity of monoclonal antibodies with the cytotoxic potency of small molecule drugs. Components include: the antibody (targets tumor-specific antigen), the linker (connects drug to antibody, cleavable or non-cleavable), and the payload (highly potent cytotoxic agent like auristatins, maytansinoids, or camptothecins). Mechanism: ADC binds to target antigen on cancer cells, is internalized via endocytosis, and releases the cytotoxic drug inside the cell. This targeted delivery reduces systemic toxicity compared to conventional chemotherapy. Key parameters include Drug-to-Antibody Ratio (DAR, typically 2-4), linker stability, and payload potency. FDA-approved ADCs include Kadcyla (breast cancer), Adcetris (lymphoma), and Enhertu (breast cancer).

Quality Control (QC) and Quality Assurance (QA) are complementary but distinct functions. QC involves testing products and processes to verify they meet specifications - reactive, focused on detecting defects. Activities include: analytical testing of raw materials, in-process samples, and final products; stability testing; release testing; and environmental monitoring. QA is a proactive system ensuring quality is built into processes. Activities include: developing SOPs and specifications; training programs; audit programs; deviation handling; change control; validation master plans; and regulatory submissions. QA sets the standards, QC verifies compliance. Together they form the quality management system required by GMP. QA is preventive (process-focused), while QC is detective (product-focused).

Herd immunity (community immunity) occurs when a sufficient proportion of a population is immune to an infectious disease, reducing its spread and protecting those who cannot be vaccinated. The threshold depends on disease transmissibility (R0): measles (R0~15) requires ~95% coverage, while less contagious diseases need lower thresholds. Importance includes: protecting vulnerable individuals who cannot be vaccinated (infants, immunocompromised, elderly); preventing outbreaks; potentially leading to disease elimination/eradication (smallpox); and reducing healthcare burden. Factors affecting herd immunity include vaccine efficacy, duration of immunity, population mixing patterns, and variant emergence. Achieving herd immunity through natural infection is undesirable due to associated morbidity and mortality.

Antibody humanization reduces immunogenicity of non-human antibodies for therapeutic use. Approaches include: 1) Chimeric antibodies - replace murine constant regions with human sequences while retaining murine variable regions; 70% human, reduced immunogenicity but still foreign V regions. 2) CDR grafting - transfer only CDRs from murine antibody onto human framework; may require back-mutations in framework to maintain binding. 3) Resurfacing - replace surface-exposed framework residues with human sequences while keeping buried residues. 4) SDR transfer - graft only Specificity Determining Residues (subset of CDRs). 5) Fully human antibodies - from transgenic mice with human antibody genes (XenoMouse) or phage/yeast display libraries. Each level of humanization balances reduced immunogenicity against maintained binding affinity and function.

mRNA vaccines deliver genetic instructions for cells to produce antigen proteins, triggering immune responses. Mechanism: lipid nanoparticles (LNPs) protect and deliver mRNA into cells; ribosomes translate mRNA into antigen protein; protein is displayed on cell surface or secreted; immune system recognizes foreign protein and develops antibodies and T-cell responses. Advantages: rapid development (weeks for sequence design), no live virus handling, no genomic integration risk, scalable manufacturing, and easily modified for variants. Challenges: cold chain requirements (LNP stability), short duration of expression, potential reactogenicity (inflammatory responses), delivery efficiency, and need for multiple doses. Key innovations include modified nucleosides (N1-methylpseudouridine) to reduce innate immune activation and optimized LNP formulations. COVID-19 vaccines validated this platform.

CHO (Chinese Hamster Ovary) cell line development involves: 1) Vector design - expression cassette with strong promoter (CMV, EF1a), gene of interest, selection marker (DHFR, GS), and regulatory elements. 2) Transfection - introduce DNA via electroporation, lipofection, or nucleofection. 3) Selection pressure - culture in selective media (methotrexate for DHFR, methionine sulfoximine for GS) to enrich stable integrants. 4) Amplification - increase selection pressure to amplify gene copies and expression. 5) Clone screening - single-cell cloning by limiting dilution, FACS, or ClonePix; screen hundreds of clones for productivity, growth, and stability. 6) Clone selection - evaluate top clones for specific productivity (pg/cell/day), product quality attributes, and genetic stability. 7) Cell banking - create Master and Working Cell Banks. Timeline: 6-12 months for high-producing stable pools, longer for clonal cell lines.

Pharmacokinetics (what body does to drug) parameters: Cmax (peak concentration), Tmax (time to peak), AUC (area under curve, total exposure), half-life (t1/2, time for 50% elimination - longer for antibodies, ~21 days due to FcRn recycling), clearance (volume cleared per time), and volume of distribution (apparent distribution space). Bioavailability for subcutaneous administration is typically 50-80%. Pharmacodynamics (what drug does to body) describes drug effect over time: Emax (maximum effect), EC50 (concentration for 50% effect), receptor occupancy, and duration of response. PK/PD modeling relates exposure to response, guiding dose selection. Biologics differ from small molecules: larger, target-mediated drug disposition (TMDD), immunogenicity affecting PK, longer half-lives, and less tissue penetration. Understanding PK/PD enables optimal dosing regimens.

Cold chain maintains vaccines at recommended temperatures from manufacturing to administration. Requirements vary: standard vaccines (2-8C), some live vaccines need freezing (-15 to -25C), mRNA vaccines required ultra-cold (-60 to -80C for Pfizer, -25 to -15C for Moderna after formulation improvements). Cold chain components: validated refrigerators/freezers with continuous monitoring, temperature data loggers, insulated transport containers with coolants, cold boxes and vaccine carriers for last mile. Challenges include: power outages, equipment failure, temperature excursions during transport, last-mile delivery in developing regions. Solutions: solar refrigerators, freeze indicators, heat-stable formulations, dry ice or liquid nitrogen for ultra-cold. Temperature excursions may require vaccine discard or stability evaluation. WHO prequalification includes cold chain requirements.

Fc engineering modifies antibody effector functions for therapeutic purposes. Strategies include: 1) Enhanced ADCC - mutations increasing FcgammaRIIIa binding (S239D/I332E, afucosylation through glycoengineering); obinutuzumab for CLL. 2) Enhanced CDC - mutations increasing C1q binding (K326W/E333S). 3) Silenced effector functions - for blocking/neutralizing antibodies where cytotoxicity is undesired; mutations L234A/L235A/P329G (LALA-PG). 4) Extended half-life - YTE mutations (M252Y/S254T/T256E) increase FcRn binding at pH 6, extending half-life 2-4 fold. 5) Bispecific formats - knobs-into-holes, CrossMab, DuoBody enable heterodimeric Fc pairing. 6) Fc fusion proteins - attach Fc to extend half-life of peptides/proteins (etanercept). These modifications enable optimization for specific therapeutic applications.

Glycosylation (attachment of sugar chains) affects therapeutic protein properties: 1) Efficacy - antibody effector functions depend on Fc glycans; afucosylated antibodies have enhanced ADCC. 2) Stability - glycans protect from aggregation and degradation. 3) Pharmacokinetics - sialylation affects clearance through asialoglycoprotein receptor. 4) Immunogenicity - non-human glycans (alpha-Gal, NGNA) can trigger immune responses. 5) Solubility - glycans increase hydrophilicity. Control strategies: cell line selection (CHO produces human-like glycans), media optimization (manganese, galactose supplementation), process parameters (pH, temperature, dissolved oxygen), gene knockout/knockin (FUT8 knockout for afucosylation), and in vitro glycoengineering. Glycan analysis (LC-MS, HILIC, capillary electrophoresis) monitors consistency. Critical quality attribute requiring tight control for biosimilar development.

Immunogenicity (immune response to therapeutic proteins) assessment involves: 1) Tiered testing approach - screening assay (sensitive, detects all ADA), confirmatory assay (specific, confirms positive screens), characterization (neutralizing activity, isotype, epitope mapping). 2) Assay formats - bridging ELISA or electrochemiluminescence (MSD) for screening; cell-based assays for neutralizing antibodies. 3) Drug tolerance - free drug interferes with ADA detection; acid dissociation, solid-phase extraction, or target interference mitigation needed. 4) Clinical correlation - relate ADA to PK changes, loss of efficacy, hypersensitivity, and cross-reactivity to endogenous proteins. 5) Risk assessment - patient factors (immune status, genetic predisposition), product factors (sequence, aggregates, glycosylation), and treatment factors (route, dose, duration). Pre-clinical assessment uses transgenic mice or non-human primates. Cut-point determination crucial for assay validation.

High-throughput screening rapidly tests large compound libraries against biological targets. Components: 1) Assay development - biochemical assays (enzyme inhibition, binding), cell-based assays (reporter genes, phenotypic), or biophysical methods (SPR, thermal shift). 2) Assay miniaturization - 384 or 1536-well plates reduce reagent use and increase throughput. 3) Automation - robotic liquid handlers, plate readers, stackers enable thousands of tests per day. 4) Compound libraries - diversity libraries, fragment libraries, natural products, or focused sets. 5) Data analysis - identify hits above threshold, Z-factor quality metric, dose-response confirmation. 6) Hit validation - confirm hits in orthogonal assays, assess selectivity, eliminate artifacts (fluorescence interference, compound reactivity). Virtual/in silico screening computationally prioritizes compounds before testing. Fragment-based screening identifies small molecules for fragment-growing optimization.

Viral vector vaccines use modified viruses to deliver antigen genes into host cells. Mechanism: replication-deficient virus (adenovirus, MVA, VSV) is engineered to carry antigen gene; vector infects cells and expresses antigen; immune system responds to antigen. Types: non-replicating (most common, single round of infection) and replicating (attenuated, amplifies antigen). Advantages: strong cellular and humoral immunity, single-dose potential, established manufacturing, stability at refrigerator temperatures, and effective antigen presentation. Limitations: pre-existing immunity to vector (especially common adenoviruses) can reduce efficacy; anti-vector immunity limits boosting with same vector; rare adverse events (thrombosis with Ad26 vectors); complex manufacturing; and dose limitations. Solutions include using rare serotypes (Ad26) or non-human adenoviruses (chimpanzee). COVID-19 vaccines (AstraZeneca, J&J) demonstrated platform capability.

Bispecific antibodies (bsAbs) bind two different antigens simultaneously, enabling novel mechanisms. Formats include: 1) IgG-like - CrossMab, knobs-into-holes, DuoBody; retain Fc functions and half-life. 2) Fragment-based - BiTE (tandem scFv, small, short half-life), DART, diabodies; easier manufacturing but need half-life extension. 3) Asymmetric - different binding arms for distinct targets. 4) Appended - additional binding domains fused to IgG. Mechanisms: T-cell engagement (CD3 x tumor antigen, like blinatumomab for leukemia); dual pathway blocking (EGFR x MET); enhanced specificity (requiring two targets for activity); bridging (Factor IXa x X for hemophilia); and piggyback delivery across barriers. Manufacturing challenges include chain pairing (light chain/heavy chain mispairing) and expression balance. Over 100 bsAbs in clinical development.

Potency assays measure biological activity of biopharmaceuticals, required for lot release. Development involves: 1) Mechanism understanding - identify relevant biological activity reflecting therapeutic effect. 2) Assay selection - cell-based assays (proliferation, reporter genes, cytotoxicity), binding assays (ELISA, SPR), or enzymatic assays depending on product. Cell-based preferred as they measure functional activity. 3) Reference standard - establish and qualify primary reference; working standards for routine use. 4) Assay format - dose-response curve with parallelism assessment between sample and reference; report relative potency. 5) Validation - accuracy, precision, linearity, range, specificity, robustness according to ICH guidelines. 6) Statistical analysis - parallel line analysis (4-parameter logistic fitting) for relative potency calculation. Challenges include assay variability, relevant cell lines, and correlating in vitro potency with clinical efficacy. Surrogate assays may be used with justified correlation.

Protein aggregation compromises safety (immunogenicity) and efficacy. Causes: 1) Physical stress - agitation, freezing/thawing, shear stress. 2) Chemical stress - oxidation, deamidation, fragmentation. 3) Thermal stress - temperature excursions. 4) Interfaces - air-water, ice-water, container surfaces. 5) Concentration - high protein concentrations increase collision probability. Prevention strategies: Formulation - stabilizing excipients (sugars like sucrose/trehalose, surfactants like polysorbate 80, amino acids like arginine), pH optimization (away from pI), ionic strength. Process - controlled mixing, minimize freeze-thaw cycles, appropriate filters/tubing materials. Container - suitable materials, surfactant-coated, minimize headspace. Storage - appropriate temperature, protected from light. Monitoring - SEC, DLS, turbidity, subvisible particle counting. Quality control limits for aggregates (typically <1-2%). Visible particles absolutely not acceptable.

CAR-T (Chimeric Antigen Receptor T-cell) therapy engineers patient's T cells to target cancer. CAR structure: extracellular antigen-binding domain (scFv), hinge, transmembrane domain, and intracellular signaling domains (CD3zeta plus co-stimulatory domains CD28 or 4-1BB). Manufacturing: 1) Leukapheresis - collect patient's blood and isolate T cells. 2) Activation - stimulate T cells with anti-CD3/CD28 beads or antibodies. 3) Transduction - introduce CAR gene using lentiviral or retroviral vectors. 4) Expansion - grow cells in bioreactors (10-14 days) to achieve therapeutic dose. 5) Formulation - cryopreserve and ship to treatment site. 6) Infusion - after lymphodepleting chemotherapy. Challenges: vein-to-vein time (3-4 weeks), manufacturing failures, cytokine release syndrome (CRS), neurotoxicity, cost ($400K+), and resistance. FDA-approved products target CD19 (Kymriah, Yescarta for lymphoma) and BCMA (Abecma for myeloma).

Analytical method validation demonstrates method fitness for intended purpose per ICH Q2 guidelines. Parameters include: 1) Specificity/selectivity - ability to detect analyte in presence of other components; stress studies, placebo interference. 2) Accuracy - closeness to true value; spike recovery or comparison to reference method. 3) Precision - repeatability (same conditions), intermediate precision (different days/analysts/equipment), reproducibility (different labs). 4) Linearity - proportional response across concentration range; regression analysis, residual plots. 5) Range - interval with acceptable accuracy and precision. 6) Limit of detection (LOD) and quantitation (LOQ) - for impurity methods. 7) Robustness - response to small deliberate variations in parameters. Additional for biologics: stability-indicating nature (detect degradants), system suitability criteria, and reference standard qualification. Method transfer validated when transferring between labs. Lifecycle approach includes continuous verification.

Biosimilar development follows a stepwise totality-of-evidence approach: 1) Analytical similarity (foundation) - extensive physicochemical characterization comparing biosimilar to reference product; primary structure, higher-order structure, post-translational modifications, purity, aggregates, particles. Functional assays for biological activity. Multiple batches of reference from different markets. 2) Animal studies - comparative PK, toxicity if needed; often abbreviated or waived. 3) Clinical pharmacology - PK/PD similarity studies demonstrating equivalent exposure and response. 4) Clinical efficacy/safety - at least one adequately powered comparative trial in sensitive population demonstrating equivalent efficacy (typically 90% CI within 80-125% margin). 5) Immunogenicity - comparative ADA assessment. Extrapolation to other indications based on mechanism of action and scientific justification. Interchangeability requires additional switching studies in US. Total development: 5-8 years, $100-200M vs $1-2B for new biologics.

Vaccine efficacy and effectiveness measure different aspects of vaccine performance: Efficacy - measured in controlled clinical trials; compares disease incidence between vaccinated and placebo groups under ideal conditions; calculated as VE = (1 - RR) x 100% where RR is risk ratio. Trials use strict enrollment criteria, standardized administration, and close monitoring. Effectiveness - measured in real-world settings post-licensure; accounts for actual implementation including diverse populations, varying storage conditions, partial adherence, and circulating variants. Often lower than efficacy due to these factors. Both express percentage reduction in disease risk. Example: 95% efficacy means vaccinated group had 95% fewer cases than placebo. Effectiveness studies use observational designs (case-control, cohort). Both are important: efficacy for licensure decisions, effectiveness for public health policy and ongoing evaluation.

FDA and ICH guidance describe three-stage lifecycle approach to process validation: Stage 1 - Process Design: Define commercial process based on development knowledge; identify critical quality attributes (CQAs), critical process parameters (CPPs), and proven acceptable ranges; establish control strategy; risk assessments (FMEA); small-scale studies and DoE to understand parameter interactions. Stage 2 - Process Qualification: PPQ (Process Performance Qualification) runs at commercial scale; demonstrate process consistently produces quality product; typically 3+ consecutive successful batches; prospective validation before commercial distribution; qualification of equipment and utilities. Stage 3 - Continued Process Verification: Ongoing assurance of validated state; statistical monitoring of process parameters and quality attributes; trend analysis; identify improvement opportunities; revalidation triggers. Supports continuous improvement rather than one-time validation event. Concurrent validation acceptable in limited circumstances.

Lead optimization transforms initial hit compounds into drug candidates with improved properties. Parameters optimized: 1) Potency - improve target affinity through SAR (structure-activity relationship) studies; typically seek nM to pM range for biologics. 2) Selectivity - reduce off-target activity; assess against related targets and broader panels. 3) ADME properties - absorption, distribution, metabolism, excretion; for biologics: PK, tissue penetration, stability. 4) Safety - minimize toxicity, genotoxicity, hERG liability. 5) Drug-like properties - appropriate MW, solubility, stability. 6) Manufacturability - synthetic feasibility, scalability, cost. Approaches include: medicinal chemistry modifications, computational modeling (docking, QSAR), fragment growing/linking, parallel synthesis for SAR exploration, and developability assessment. For antibodies: affinity maturation, humanization, Fc engineering, format optimization. Iterative cycles of design-make-test-analyze. Stage-gates evaluate candidates against target product profile.

Continuous manufacturing runs processes without interruption, as opposed to traditional batch processing. Implementation in biologics: 1) Upstream - perfusion bioreactors maintain steady-state culture with continuous harvest; ATF or TFF for cell retention. 2) Downstream - integrated continuous chromatography (multi-column, periodic counter-current), in-line virus inactivation, continuous filtration, real-time blending. Advantages: smaller equipment footprint (5-10x smaller), reduced capital costs, consistent product quality (steady-state operation), real-time process monitoring and control, faster processing (no hold times), flexible production scale (by run time), and reduced material loss. Challenges: complex process control, need for robust analytics (PAT), regulatory framework still evolving, validation requirements, and change management. FDA supports continuous manufacturing with guidance documents. Adopted more in small molecules; biologics implementation growing.

Next-generation antibody engineering creates novel formats addressing IgG limitations: 1) Antibody fragments - Fab, scFv, VHH (nanobodies from camelids); smaller size enables tissue penetration but shorter half-life. 2) Half-life extended fragments - Fc fusion, albumin binding, PEGylation extend nanobody half-life. 3) Multi-specific formats - trispecifics, tetraspecifics for complex biology (T-cell redirection plus costimulation). 4) Conditional activation - probodies masked until cleaved by tumor proteases; Cytomx platform. 5) Intracellular antibodies - cell-penetrating peptides or mRNA delivery for intracellular targets. 6) Antibody-cytokine fusions (immunocytokines) - target cytokines to tumor microenvironment. 7) Fc-engineered formats - enhanced or silenced effector functions. 8) Multivalent constructs - increased avidity through multiple binding sites. 9) pH-sensitive antibodies - recycling antibodies that release target in endosome and recycle. Each format optimizes for specific therapeutic application.

Rapid pandemic vaccine development requires pre-positioning and platform technologies: 1) Platform technologies - mRNA and viral vectors enable rapid antigen sequence insertion without de novo development; reduced from years to months. 2) Pre-clinical preparedness - libraries of characterized vectors, validated manufacturing processes, stockpiled materials. 3) At-risk manufacturing - scale up before Phase 3 completion; government funding absorbs financial risk. 4) Adaptive trial designs - rolling submissions, master protocols, accelerated enrollment. 5) Regulatory agility - emergency use authorization, rolling review, international harmonization. 6) Distributed manufacturing - technology transfer to multiple sites globally. Trade-offs: compressed timelines vs long-term safety data (particularly rare adverse events); emergency use vs full approval confidence; variant adaptation vs verification studies; speed vs supply chain robustness. Lessons from COVID-19 informing pandemic preparedness plans, prototype pathogen approach for priority pathogens, and 100-day vaccine goal.

Quality by Design (QbD) systematically builds quality into biologics development per ICH Q8-Q12: 1) Target Product Profile (TPP) - define clinical and quality requirements for intended use. 2) Critical Quality Attributes (CQAs) - identify quality attributes impacting safety/efficacy (potency, purity, aggregates, glycosylation, charge variants). 3) Critical Process Parameters (CPPs) - process variables affecting CQAs (pH, temperature, DO, feed rates). 4) Design Space - multidimensional combination of inputs and process parameters providing acceptable quality; operating within design space is not a regulatory change. 5) Control Strategy - planned controls based on process understanding (in-process, PAT, real-time release). 6) Risk Assessment - FMEA, cause-and-effect diagrams to prioritize parameters. 7) Lifecycle Management - continuous improvement within design space. Implementation: DoE for process characterization, multivariate analysis, mechanistic modeling. Benefits: reduced batch failures, increased process understanding, regulatory flexibility, enhanced continuous improvement.

Cell and gene therapy manufacturing faces unique challenges: 1) Autologous processing - patient-specific manufacturing (CAR-T); chain of identity critical; vein-to-vein time (3-4 weeks); limited scale-up; capacity constraints. 2) Allogeneic approaches - off-the-shelf products address scalability but face immunological barriers; gene editing for HLA knockout. 3) Viral vector production - transfection-based systems have lot-to-lot variability; stable producer cell lines emerging; limiting for gene therapies requiring high doses (1e14+ vg for DMD). 4) Quality control - potency assays challenging for complex therapies; identity testing; sterility for living products. 5) Closed processing - reduce contamination and facility classification requirements. 6) Supply chain - specialized materials (plasmids, viral vectors, GMP-grade cytokines). 7) Automation - reduce manual operations and variability; CliniMACS Prodigy, Miltenyi Tyto. 8) Cost - current costs >$300K unsustainable; platform approaches, automation, and scale addressing. Regulatory frameworks continue evolving.

Protein engineering optimizes properties through two complementary approaches: Rational Design: Uses structural and mechanistic knowledge to make targeted mutations. Methods include structure-guided design (modify active site, introduce stabilizing mutations), computational approaches (Rosetta, FoldX for stability, binding predictions), and machine learning models. Advantages: efficient when mechanism understood, predictable outcomes. Limitations: requires structural knowledge, may miss unexpected solutions. Directed Evolution: Mimics natural selection through iterative mutation and screening. Methods: error-prone PCR, DNA shuffling, site-saturation mutagenesis (generating diversity); screening or selection for improved variants. Display technologies: phage display, yeast display, ribosome display enable large libraries (10^8-10^12). Advantages: requires no structural knowledge, can achieve unexpected improvements. Limitations: library coverage, screening throughput. Combined approaches: Semi-rational design focuses diversity on key positions; machine learning guides mutagenesis based on sequence-function relationships. Frances Arnold (Nobel 2018) pioneered directed evolution for enzymes and antibodies.

Universal flu vaccine aims to provide broad, durable protection against diverse strains, eliminating need for annual reformulation. Approaches: 1) Hemagglutinin stalk antibodies - target conserved HA stalk region rather than variable head; chimeric HA vaccines, headless HA constructs, computationally designed immunogens. 2) Neuraminidase targeting - NA is more conserved than HA head; anti-NA antibodies contribute to protection. 3) M2 ectodomain (M2e) - highly conserved but weakly immunogenic; fusion constructs and VLPs being developed. 4) Conserved internal proteins - NP and M1 for T-cell responses; important for cross-protection. 5) Mosaic/cocktail vaccines - combine multiple HA subtypes to broaden response. 6) Novel adjuvants - enhance responses to conserved epitopes. 7) mRNA platform - rapid antigen updating and potential multivalent approaches. Challenges: overcoming immunodominance of variable regions, correlates of protection less defined for stalk antibodies, T-cell immunity difficult to measure. NIH-funded trials ongoing; universal coverage remains 5-10+ years away.

Bioassay statistical analysis extracts potency information from dose-response data: 1) Parallel line analysis - classic approach assuming parallel dose-response curves for sample and reference; linear portion of log-dose vs response analyzed. 2) Four-parameter logistic (4PL) regression - fits sigmoid curves: Response = Bottom + (Top-Bottom)/(1 + 10^((LogEC50-LogDose)*HillSlope)). Relative potency calculated from EC50 shift. 3) Parallelism assessment - evaluate if curves are parallel (same slope, shape); f-test or equivalence testing; non-parallel curves indicate quality issues. 4) Confidence intervals - 95% CI for potency typically required within 80-125% for lot release. 5) Weighted regression - appropriate when variance is non-constant. 6) Combination indices - for assays with multiple responses. Regulatory expectations: USP chapters 1032-1034 guidance, EDQM biostatistics, and CombiStats software. Key: assay qualification establishes acceptable precision; system suitability ensures each run is valid.

ADC optimization balances efficacy, safety, and manufacturability across multiple parameters: 1) Antibody selection - target expression (tumor-specific, internalization-competent), trafficking (lysosomal delivery for cleavable linkers), binding kinetics, and species cross-reactivity for preclinical. 2) Drug-to-Antibody Ratio (DAR) - higher DAR increases potency but may reduce stability and increase hydrophobicity; typically DAR 2-4; site-specific conjugation controls DAR precisely. 3) Linker chemistry - cleavable (valine-citrulline cleaved by cathepsins, disulfide reduction, hydrazone at low pH) vs non-cleavable (requires antibody degradation); stability in circulation vs efficient release in target. 4) Payload - potency (pM IC50), mechanism (tubulin inhibitors, DNA alkylators, RNA polymerase inhibitors), bystander effect, resistance mechanisms. 5) Conjugation site - interchain cysteines (heterogeneous), engineered cysteines (THIOMAB), unnatural amino acids, enzymatic (transglutaminase, sortase); site affects PK, stability, efficacy. 6) Biophysical properties - aggregation, viscosity for manufacturing. Integrated assessment required.

Regulatory strategy aligns development with approval requirements across jurisdictions: 1) Early planning - define Target Product Profile, regulatory pathway (standard vs accelerated), and global filing strategy. 2) Regulatory designations - orphan drug (7-year exclusivity US, 10 EU), breakthrough therapy (intensive FDA guidance), PRIME (EMA), fast track, accelerated approval based on surrogate endpoints. 3) Agency interactions - pre-IND meetings, Type B meetings, scientific advice; align on endpoints, patient populations, comparators, manufacturing requirements. 4) Clinical development - adaptive designs, master protocols, real-world evidence; negotiate registration-enabling trial designs. 5) Chemistry, Manufacturing, Controls (CMC) - phased approach to controls; comparability for process changes; establish acceptable specifications. 6) Global harmonization - ICH guidelines alignment; reference product selection for biosimilars; address regional differences (China NMPA, Japan PMDA requirements). 7) Post-market commitments - REMS, Phase IV studies, label updates. Risk-based approach prioritizing critical path elements.

PAT enables real-time process monitoring and control per ICH Q8/Q9/Q10 and FDA PAT guidance: 1) Spectroscopic methods - Raman spectroscopy for glucose, amino acids, product titer; NIR for moisture, concentration; UV for protein. 2) In-line sensors - DO, pH, viable cell density (capacitance), biomass, temperature with feedback control. 3) At-line/on-line analytics - HPLC for glycan profiles, CE for charge variants, cell counters. 4) Multivariate data analysis - PCA, PLS models correlate spectral data to attributes; detect process deviations. 5) Real-Time Release Testing (RTRT) - replace end-product testing with in-process data; requires validated models. 6) Digital twins - mechanistic or hybrid models predict process outcomes. Implementation considerations: sensor robustness in bioprocess environment, model maintenance and recalibration, integration with automation/SCADA systems, regulatory acceptance of RTRT. Benefits: reduced batch failures through early deviation detection, enhanced process understanding, potential for continuous manufacturing, and reduced QC testing time.

Vaccine thermostability reduces cold chain requirements, critical for global access. Strategies: 1) Formulation optimization - stabilizing excipients (sugars as glass-formers: trehalose, sucrose; amino acids; surfactants); buffer selection (histidine, phosphate); pH optimization; removal of destabilizing components. 2) Lyophilization - freeze-drying removes water, increasing stability; cycle optimization critical; reconstitution considerations. 3) Spray drying - produces thermostable powder; emerging for vaccines. 4) Controlled Temperature Chain (CTC) - WHO prequalification allowing single excursion to 40C for defined time. 5) Microencapsulation - protect antigens in polymer matrices. 6) Structural engineering - stabilize proteins through mutations; prefusion-stabilized RSV vaccines. 7) Thermostable platforms - some viral vectors and VLPs inherently stable. 8) Sugar glass technology - amorphous sugar matrices preserve antigens. Assessment: accelerated stability studies, Arrhenius kinetics for shelf-life prediction, real-time stability. mRNA vaccines remain challenge due to hydrolysis susceptibility.

Biologics pharmacovigilance addresses unique safety considerations: 1) Immunogenicity monitoring - long-term ADA development, neutralizing antibodies, impact on PK and efficacy, cross-reactive antibodies to endogenous proteins (pure red cell aplasia with erythropoietin). 2) Batch traceability - track specific batches to patients; essential for investigating batch-related issues; unique identifier requirements. 3) Product-specific events - class effects may not apply across similar products; each product requires independent safety database. 4) Biosimilar extrapolation - safety data from one indication may support others, but monitoring required. 5) Signal detection - rare events require large exposed populations; post-marketing studies, registries. 6) Immunologically-mediated events - cytokine release syndrome (CAR-T), infusion reactions, immune-complex deposition. 7) Risk minimization - REMS programs, restricted distribution, healthcare provider certification. 8) Pregnancy registries - limited data, need for exposure registries. Collaboration between manufacturers, regulators, and healthcare systems essential.

Oncolytic viruses (OVs) selectively replicate in and lyse tumor cells while stimulating anti-tumor immunity. Mechanisms: 1) Tumor selectivity - through defective interferon responses in tumors, tumor-specific receptors, or engineered selectivity (tissue-specific promoters, microRNA targeting). 2) Direct lysis - replication leads to cell death and release of tumor antigens. 3) Immune activation - danger signals (DAMPs, PAMPs), immunogenic cell death, and tumor antigen presentation generate systemic anti-tumor immunity. Armed OVs: Express cytokines (GM-CSF in T-VEC), checkpoint inhibitors, or bispecific T-cell engagers for enhanced efficacy. Development considerations: pre-existing immunity to viral backbone (HSV, adenovirus); immunogenicity limiting repeated dosing; delivery (intratumoral vs systemic); biodistribution and shedding; manufacturing (high titers, purity, identity testing); combination with checkpoint inhibitors showing promise. FDA-approved: T-VEC (talimogene laherparepvec) for melanoma. Active development in multiple tumor types.

Comparability demonstrates equivalent product quality after manufacturing changes: 1) Risk assessment - categorize change magnitude and potential quality impact; determine testing scope. ICH Q5E provides framework. 2) Analytical comparability - extensive physicochemical characterization (primary structure, higher-order structure, PTMs, purity profiles, potency); multiple batches before and after; statistical equivalence testing. 3) Functional assessment - mechanism-relevant bioassays; receptor binding; effector functions. 4) Stability - confirm comparable stability profiles; accelerated and real-time studies. 5) Non-clinical studies - PK, toxicity if significant change; often bridging studies sufficient. 6) Clinical bridging - may require PK study demonstrating comparable exposure; efficacy/safety studies rarely needed for well-characterized products. Regulatory strategy: prospective agency engagement for major changes; post-approval change protocols for anticipated changes. Comparability protocol in BLA/MAA allows pre-defined changes without prior approval. Documentation must clearly demonstrate no adverse impact on safety, identity, purity, or potency.

In silico immunogenicity tools inform protein design and risk assessment: 1) T-cell epitope prediction - identify peptide sequences binding MHC Class II; algorithms (NetMHCIIpan, IEDB) trained on binding data; predict CD4+ T-helper epitopes critical for antibody responses. 2) Deimmunization - identify and mutate immunogenic sequences while maintaining function; iterate design to reduce epitope content. 3) Population coverage - assess epitope binding across HLA allele frequencies in different populations. 4) Aggregation prediction - aggregates enhance immunogenicity; predict aggregation-prone regions (AGGRESCAN, Zyggregator). 5) Comparison to human sequences - identify non-human sequences that may be immunogenic. 6) Regulatory peptides (Tregitopes) - include sequences that may induce tolerance. Limitations: prediction accuracy ~70-80%; MHC binding necessary but not sufficient for immunogenicity; does not capture B-cell epitopes well; post-translational modifications not fully addressed. Best used as part of integrated assessment with ex vivo assays (DC-T cell assays, PBMC stimulation) and clinical immunogenicity data.